Your browser is no longer supported. Please, upgrade your browser.
Settings
DMTK DermTech, Inc. daily Stock Chart
DMTK [NASD]
DermTech, Inc.
Index- P/E96.72 EPS (ttm)0.14 Insider Own13.00% Shs Outstand11.98M Perf Week30.80%
Market Cap158.74M Forward P/E- EPS next Y-1.89 Insider Trans0.00% Shs Float6.63M Perf Month6.77%
Income0.70M PEG- EPS next Q-0.40 Inst Own42.80% Short Float1.82% Perf Quarter90.57%
Sales2.40M P/S66.03 EPS this Y396.40% Inst Trans- Short Ratio1.98 Perf Half Y-35.68%
Book/sh1.09 P/B12.16 EPS next Y39.00% ROA0.90% Target Price15.00 Perf Year-33.62%
Cash/sh0.00 P/C- EPS next 5Y- ROE1.00% 52W Range4.52 - 23.24 Perf YTD6.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.99% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low193.14% ATR1.04
Employees36 Current Ratio0.00 Sales Q/Q-11.90% Oper. Margin- RSI (14)64.35 Volatility8.74% 10.16%
OptionableNo Debt/Eq0.00 EPS Q/Q-19.60% Profit Margin- Rel Volume0.47 Prev Close13.03
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 Payout0.00% Avg Volume60.81K Price13.25
Recom2.00 SMA2016.64% SMA5024.51% SMA200-6.57% Volume28,722 Change1.69%
Dec-05-19Initiated Lake Street Buy
Jan-16-20 05:45PM  DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contract for the Pigmented Lesion Assay Business Wire
Jan-08-20 08:00AM  CMS Releases Final 2020 Clinical Lab Fee Schedule (CLFS) Including Pricing for DermTechs Pigmented Lesion Assay (PLA) Business Wire -10.88%
Jan-02-20 08:00AM  DermTechs Pigmented Lesion Assay (PLA) Receives Medicare Coverage Business Wire
Nov-07-19 01:30PM  DermTech, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire +6.89%
Nov-06-19 02:28PM  DermTech to Present at Upcoming Investor Conferences Business Wire
Oct-28-19 08:00AM  DermTech Receives CPT® Proprietary Laboratory Assay Code from the American Medical Association Business Wire
Oct-22-19 08:00AM  DermTech Presents New Data at Fall Clinical Dermatology Conference Business Wire -9.28%
Oct-18-19 04:15PM  DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital Market Business Wire
Oct-15-19 08:00AM  DermTechs Test Included in Expert Panels Clinical Management Recommendations for Cutaneous Melanoma Business Wire
Oct-07-19 08:00AM  DermTech Further Expands Patent Portfolio Business Wire
Sep-16-19 04:30PM  DermTech Announces Appointment of Kevin Sun as Chief Financial Officer Business Wire
DermTech, Inc., a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California.